Cargando…
Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels
The potential therapeutic effects of probiotic bacteria in rheumatoid arthritis (RA) remain controversial. Thus, this study aimed to discover potential therapeutic bacteria based on the relationship between the gut microbiome and rheumatoid factor (RF) in RA. Bacterial genomic DNA was extracted from...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634832/ https://www.ncbi.nlm.nih.gov/pubmed/34867956 http://dx.doi.org/10.3389/fimmu.2021.736196 |
_version_ | 1784608193010204672 |
---|---|
author | Jeong, Yunju Jhun, JooYeon Lee, Seon-Yeong Na, Hyun Sik Choi, JeongWon Cho, Keun-Hyung Lee, Seung Yoon Lee, A Ram Park, Sang-Jun You, Hyun Ju Kim, Ji-Won Park, Myeong Soo Kwon, Bin Cho, Mi-La Ji, Geun Eog Park, Sung-Hwan |
author_facet | Jeong, Yunju Jhun, JooYeon Lee, Seon-Yeong Na, Hyun Sik Choi, JeongWon Cho, Keun-Hyung Lee, Seung Yoon Lee, A Ram Park, Sang-Jun You, Hyun Ju Kim, Ji-Won Park, Myeong Soo Kwon, Bin Cho, Mi-La Ji, Geun Eog Park, Sung-Hwan |
author_sort | Jeong, Yunju |
collection | PubMed |
description | The potential therapeutic effects of probiotic bacteria in rheumatoid arthritis (RA) remain controversial. Thus, this study aimed to discover potential therapeutic bacteria based on the relationship between the gut microbiome and rheumatoid factor (RF) in RA. Bacterial genomic DNA was extracted from the fecal samples of 93 RA patients and 16 healthy subjects. Microbiota profiling was conducted through 16S rRNA sequencing and bioinformatics analyses. The effects of Bifidobacterium strains on human peripheral blood mononuclear cells and collagen-induced arthritis (CIA) mice were assessed. Significant differences in gut microbiota composition were observed in patients with different RF levels. The relative abundance of Bifidobacterium and Collinsella was lower in RF-high than in RF-low and RF-negative RA patients, while the relative abundance of Clostridium of Ruminococcaceae family was higher in RF-high than in RF-low and RF-negative patients. Among 10 differentially abundant Bifidobacterium, B. longum RAPO exhibited the strongest ability to inhibit IL-17 secretion. Oral administration of B. longum RAPO in CIA mice, obese CIA, and humanized avatar model significantly reduced RA incidence, arthritis score, inflammation, bone damage, cartilage damage, Th17 cells, and inflammatory cytokine secretion. Additionally, B. longum RAPO significantly inhibited Th17 cells and Th17-related genes—IL-17A, IRF4, RORC, IL-21, and IL-23R—in the PBMCs of rheumatoid arthritis patients. Our findings suggest that B. longum RAPO may alleviate RA by inhibiting the production of IL-17 and other proinflammatory mediators. The safety and efficacy of B. longum RAPO in patients with RA and other autoimmune disorders merit further investigation. |
format | Online Article Text |
id | pubmed-8634832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86348322021-12-02 Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels Jeong, Yunju Jhun, JooYeon Lee, Seon-Yeong Na, Hyun Sik Choi, JeongWon Cho, Keun-Hyung Lee, Seung Yoon Lee, A Ram Park, Sang-Jun You, Hyun Ju Kim, Ji-Won Park, Myeong Soo Kwon, Bin Cho, Mi-La Ji, Geun Eog Park, Sung-Hwan Front Immunol Immunology The potential therapeutic effects of probiotic bacteria in rheumatoid arthritis (RA) remain controversial. Thus, this study aimed to discover potential therapeutic bacteria based on the relationship between the gut microbiome and rheumatoid factor (RF) in RA. Bacterial genomic DNA was extracted from the fecal samples of 93 RA patients and 16 healthy subjects. Microbiota profiling was conducted through 16S rRNA sequencing and bioinformatics analyses. The effects of Bifidobacterium strains on human peripheral blood mononuclear cells and collagen-induced arthritis (CIA) mice were assessed. Significant differences in gut microbiota composition were observed in patients with different RF levels. The relative abundance of Bifidobacterium and Collinsella was lower in RF-high than in RF-low and RF-negative RA patients, while the relative abundance of Clostridium of Ruminococcaceae family was higher in RF-high than in RF-low and RF-negative patients. Among 10 differentially abundant Bifidobacterium, B. longum RAPO exhibited the strongest ability to inhibit IL-17 secretion. Oral administration of B. longum RAPO in CIA mice, obese CIA, and humanized avatar model significantly reduced RA incidence, arthritis score, inflammation, bone damage, cartilage damage, Th17 cells, and inflammatory cytokine secretion. Additionally, B. longum RAPO significantly inhibited Th17 cells and Th17-related genes—IL-17A, IRF4, RORC, IL-21, and IL-23R—in the PBMCs of rheumatoid arthritis patients. Our findings suggest that B. longum RAPO may alleviate RA by inhibiting the production of IL-17 and other proinflammatory mediators. The safety and efficacy of B. longum RAPO in patients with RA and other autoimmune disorders merit further investigation. Frontiers Media S.A. 2021-11-15 /pmc/articles/PMC8634832/ /pubmed/34867956 http://dx.doi.org/10.3389/fimmu.2021.736196 Text en Copyright © 2021 Jeong, Jhun, Lee, Na, Choi, Cho, Lee, Lee, Park, You, Kim, Park, Kwon, Cho, Ji and Park https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Jeong, Yunju Jhun, JooYeon Lee, Seon-Yeong Na, Hyun Sik Choi, JeongWon Cho, Keun-Hyung Lee, Seung Yoon Lee, A Ram Park, Sang-Jun You, Hyun Ju Kim, Ji-Won Park, Myeong Soo Kwon, Bin Cho, Mi-La Ji, Geun Eog Park, Sung-Hwan Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels |
title | Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels |
title_full | Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels |
title_fullStr | Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels |
title_full_unstemmed | Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels |
title_short | Therapeutic Potential of a Novel Bifidobacterium Identified Through Microbiome Profiling of RA Patients With Different RF Levels |
title_sort | therapeutic potential of a novel bifidobacterium identified through microbiome profiling of ra patients with different rf levels |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634832/ https://www.ncbi.nlm.nih.gov/pubmed/34867956 http://dx.doi.org/10.3389/fimmu.2021.736196 |
work_keys_str_mv | AT jeongyunju therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT jhunjooyeon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT leeseonyeong therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT nahyunsik therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT choijeongwon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT chokeunhyung therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT leeseungyoon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT leearam therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT parksangjun therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT youhyunju therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT kimjiwon therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT parkmyeongsoo therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT kwonbin therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT chomila therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT jigeuneog therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels AT parksunghwan therapeuticpotentialofanovelbifidobacteriumidentifiedthroughmicrobiomeprofilingofrapatientswithdifferentrflevels |